vs

Side-by-side financial comparison of Snap-on (SNA) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.2× Snap-on). Snap-on runs the higher net margin — 21.3% vs 12.9%, a 8.4% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 2.7%). Snap-on produced more free cash flow last quarter ($254.6M vs $199.5M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 2.0%).

Snap-on Incorporated is an American designer, manufacturer, and marketer of high-end tools and equipment for professional use in the transportation industry, including the automotive, heavy duty, equipment, marine, aviation, and railroad industries. Headquartered in Kenosha, Wisconsin, since 1930, Snap-on also distributes lower-end tools under the brand name Blue-Point. Their primary competitors include Matco, Mac Tools, and Cornwell Tools.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

SNA vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.2× larger
STE
$1.5B
$1.2B
SNA
Growing faster (revenue YoY)
STE
STE
+6.5% gap
STE
9.2%
2.7%
SNA
Higher net margin
SNA
SNA
8.4% more per $
SNA
21.3%
12.9%
STE
More free cash flow
SNA
SNA
$55.1M more FCF
SNA
$254.6M
$199.5M
STE
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
2.0%
SNA

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
SNA
SNA
STE
STE
Revenue
$1.2B
$1.5B
Net Profit
$260.7M
$192.9M
Gross Margin
43.8%
Operating Margin
27.8%
18.3%
Net Margin
21.3%
12.9%
Revenue YoY
2.7%
9.2%
Net Profit YoY
1.0%
11.2%
EPS (diluted)
$4.94
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SNA
SNA
STE
STE
Q4 25
$1.2B
$1.5B
Q3 25
$1.2B
$1.5B
Q2 25
$1.2B
$1.4B
Q1 25
$1.1B
$1.5B
Q4 24
$1.2B
$1.4B
Q3 24
$1.1B
$1.3B
Q2 24
$1.2B
$1.3B
Q1 24
$1.2B
$1.1B
Net Profit
SNA
SNA
STE
STE
Q4 25
$260.7M
$192.9M
Q3 25
$265.4M
$191.9M
Q2 25
$250.3M
$177.4M
Q1 25
$240.5M
$145.7M
Q4 24
$258.1M
$173.5M
Q3 24
$251.1M
$150.0M
Q2 24
$271.2M
$145.4M
Q1 24
$263.5M
$-1.4M
Gross Margin
SNA
SNA
STE
STE
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
43.6%
Q2 24
44.7%
Q1 24
40.2%
Operating Margin
SNA
SNA
STE
STE
Q4 25
27.8%
18.3%
Q3 25
29.4%
18.2%
Q2 25
28.0%
17.7%
Q1 25
27.7%
14.6%
Q4 24
27.9%
17.9%
Q3 24
28.4%
16.5%
Q2 24
29.9%
14.5%
Q1 24
28.9%
22.0%
Net Margin
SNA
SNA
STE
STE
Q4 25
21.3%
12.9%
Q3 25
22.5%
13.1%
Q2 25
21.4%
12.8%
Q1 25
21.2%
9.8%
Q4 24
21.7%
12.7%
Q3 24
22.0%
11.3%
Q2 24
23.1%
11.4%
Q1 24
22.4%
-0.1%
EPS (diluted)
SNA
SNA
STE
STE
Q4 25
$4.94
$1.96
Q3 25
$5.02
$1.94
Q2 25
$4.72
$1.79
Q1 25
$4.51
$1.48
Q4 24
$4.83
$1.75
Q3 24
$4.70
$1.51
Q2 24
$5.07
$1.46
Q1 24
$4.91
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SNA
SNA
STE
STE
Cash + ST InvestmentsLiquidity on hand
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$7.2B
Total Assets
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SNA
SNA
STE
STE
Q4 25
$423.7M
Q3 25
$1.5B
$319.2M
Q2 25
$1.5B
$279.7M
Q1 25
$1.4B
$171.7M
Q4 24
$1.4B
$155.2M
Q3 24
$1.3B
$172.2M
Q2 24
$1.2B
$198.3M
Q1 24
$1.1B
$207.0M
Total Debt
SNA
SNA
STE
STE
Q4 25
$1.9B
Q3 25
$1.2B
$1.9B
Q2 25
$1.2B
$1.9B
Q1 25
$1.9B
Q4 24
$1.2B
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
SNA
SNA
STE
STE
Q4 25
$7.2B
Q3 25
$5.8B
$7.0B
Q2 25
$5.7B
$7.0B
Q1 25
$5.5B
$6.6B
Q4 24
$5.4B
$6.4B
Q3 24
$5.5B
$6.6B
Q2 24
$5.3B
$6.4B
Q1 24
$5.1B
$6.3B
Total Assets
SNA
SNA
STE
STE
Q4 25
$10.6B
Q3 25
$8.4B
$10.4B
Q2 25
$8.2B
$10.4B
Q1 25
$8.1B
$10.1B
Q4 24
$7.9B
$10.0B
Q3 24
$8.0B
$10.2B
Q2 24
$7.8B
$10.1B
Q1 24
$7.7B
$11.1B
Debt / Equity
SNA
SNA
STE
STE
Q4 25
0.27×
Q3 25
0.21×
0.27×
Q2 25
0.21×
0.27×
Q1 25
0.29×
Q4 24
0.22×
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SNA
SNA
STE
STE
Operating Cash FlowLast quarter
$268.1M
$298.2M
Free Cash FlowOCF − Capex
$254.6M
$199.5M
FCF MarginFCF / Revenue
20.8%
13.3%
Capex IntensityCapex / Revenue
1.1%
6.6%
Cash ConversionOCF / Net Profit
1.03×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$1.0B
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SNA
SNA
STE
STE
Q4 25
$268.1M
$298.2M
Q3 25
$277.9M
$287.8M
Q2 25
$237.2M
$420.0M
Q1 25
$298.5M
$260.8M
Q4 24
$293.5M
$332.8M
Q3 24
$274.2M
$250.7M
Q2 24
$301.1M
$303.7M
Q1 24
$348.7M
$254.8M
Free Cash Flow
SNA
SNA
STE
STE
Q4 25
$254.6M
$199.5M
Q3 25
$258.0M
$201.3M
Q2 25
$217.5M
$326.4M
Q1 25
$275.6M
$189.9M
Q4 24
$275.4M
$243.6M
Q3 24
$253.8M
$148.8M
Q2 24
$277.9M
$195.7M
Q1 24
$326.9M
$163.3M
FCF Margin
SNA
SNA
STE
STE
Q4 25
20.8%
13.3%
Q3 25
21.8%
13.8%
Q2 25
18.6%
23.5%
Q1 25
24.3%
12.8%
Q4 24
23.1%
17.8%
Q3 24
22.3%
11.2%
Q2 24
23.7%
15.3%
Q1 24
27.8%
14.6%
Capex Intensity
SNA
SNA
STE
STE
Q4 25
1.1%
6.6%
Q3 25
1.7%
5.9%
Q2 25
1.7%
6.7%
Q1 25
2.0%
4.8%
Q4 24
1.5%
6.5%
Q3 24
1.8%
7.7%
Q2 24
2.0%
8.4%
Q1 24
1.9%
8.2%
Cash Conversion
SNA
SNA
STE
STE
Q4 25
1.03×
1.55×
Q3 25
1.05×
1.50×
Q2 25
0.95×
2.37×
Q1 25
1.24×
1.79×
Q4 24
1.14×
1.92×
Q3 24
1.09×
1.67×
Q2 24
1.11×
2.09×
Q1 24
1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SNA
SNA

Segment breakdown not available.

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons